Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis

Critical Care Medicine

Volumn 39, Issue 4, 2011, Pages 702-710

  Ricciuto, Daniel R ^a,b   Dos Santos, Claudia C ^c   Hawkes, Michael ^a   Toltl, Lisa J ^d,e   Conroy, Andrea L ^a   Rajwans, Nimerta ^a   Lafferty, Erin I ^a   Cook, Deborah J ^d   Fox Robichaud, Alison ^d   Kahnamoui, Kamyar ^d   Kain, Kevin C ^a,b   Liaw, Patricia C ^d,e   Liles, W Conrad ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

angiopoietin 1; angiopoietin 2; humans; morbidity; severe sepsis; survival

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL ACTIVATION; CLINICAL STUDY; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SEPSIS; TERTIARY HEALTH CARE;

EID: 79953218683     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318206d285     Document Type: Article

References (46)

1. Lever A, Mackenzie I: Sepsis: Definition, epidemiology, and diagnosis. BMJ 2007; 335: 879-883. (Pubitemid 350069465)
2. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554. (Pubitemid 36437931)
3. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-1256. (Pubitemid 36444440)
4. Aird WC: The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101:3765-3777. (Pubitemid 36857845)
5. Fiedler U, Augustin HG: Angiopoietins: A link between angiogenesis and inflammation. Trends Immunol 2006; 27:552-558. (Pubitemid 44780853)
6. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995; 376:70-74.
7. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277:55-60. (Pubitemid 27450643)
8. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87:1171-1180. (Pubitemid 27010101)
9. Witzenbichler B, Westermann D, Knueppel S, et al. Protective role of angiopoietin-1 in endotoxic shock. Circulation 2005; 111: 97-105. (Pubitemid 40070850)
10. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6:460-463. (Pubitemid 30208166)
11. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2005; 12: 235-239. (Pubitemid 43214752)
12. Parikh SM, Mammoto T, Schultz A, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006; 3:356-370.
13. Conroy AL, Lafferty EI, Lovegrove FE, et al. Whole blood angiopoietin-1 and -2 levels discriminate cerebral and severe (non-cerebral) malaria from uncomplicated malaria. Malar J 2009; 8:295.
14. Orfanos SE, Kotanidou A, Glynos C, et al. Angiopoietin-2 is increased in severe sepsis: Correlation with inflammatory mediators. Crit Care Med 2007; 35:199-206. (Pubitemid 46035696)
15. Lovegrove FE, Tangpukdee N, Opoka RO, et al. Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS One 2009; 4:e4912.
16. van der Heijden M, van Nieuw Amerongen GP, Koolwijk P, et al. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax 2008; 63:903-909.
17. Gallagher DC, Parikh SM, Balonov K, et al. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock 2008; 29:656-661. (Pubitemid 351769925)
18. Kranidioti H, Orfanos SE, Vaki I, et al. Angiopoietin2 is increased in septic shock: Evidence for the existence of a circulating factor stimulating its release from human monocytes. Immunol Lett 2009; 125:65-71.
19. Huang YQ, Sauthoff H, Herscovici P, et al. Angiopoietin-1 increases survival and reduces the development of lung edema induced by endotoxin administration in a murine model of acute lung injury. Crit Care Med 2008; 36:262-267.
20. Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-1652.
21. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709. (Pubitemid 32204987)
22. Bone RC, Sibbald WJ, Sprung CL: The ACCPSCCM consensus conference on sepsis and organ failure. Chest 1992; 101:1481-1483.
23. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J 2005; 47:458-472. (Pubitemid 41229379)
24. Sinuff T, Adhikari NK, Cook DJ, et al. Mortality predictions in the intensive care unit: Comparing physicians with scoring systems. Crit Care Med 2006; 34(3):878-885.
25. Barriere SL, Lowry SF: An overview of mortality risk prediction in sepsis. Crit Care Med 1995; 23:376-393.
26. Marshall JC, Reinhart K: Biomarkers of sepsis. Crit Care Med 2009; 37:2290-2298.
27. van der Heijden M, Pickkers P, van Nieuw Amerongen GP, et al. Circulating angiopoietin2 levels in the course of septic shock: relation with fluid balance, pulmonary dysfunction and mortality. Intensive Care Med 2009; 35:1567-1574.
28. Product Monograph: Quantikine Human Angiopoietin1 Immunoassay. Minneapolis, MN, R&D Systems. Catalog No. DANG10.
29. Lukasz A, Hellpap J, Horn R, et al. Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: Development and clinical application of two new immunoassays. Crit Care 2008; 12:R94.
30. Bolin M, Wiberg-Itzel E, Wikström AK, et al. Angiopoietin-1/ angiopoietin-2 ratio for prediction of preeclampsia. Am J Hypertens 2009; 22:891-895.
31. Chong AY, Caine GJ, Freestone B, et al. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol 2004; 43:423-428. (Pubitemid 38167703)
32. Mandriota SJ, Pepper MS: Regulation of angiopoietin2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 1998; 83:852-859. (Pubitemid 28489082)
33. Bhandari V, Choo-Wing R, Lee CG, et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 2006; 12:1286-1293. (Pubitemid 44706931)
34. Mofarrahi M, Nouth T, Qureshi S, et al. Regulation of angiopoietin expression by bacterial lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol 2008; 294:I.955-I.963.
35. Siner JM, Bhandari V, Engle KM, et al. Elevated serum angiopoietin 2 levels are associated with increased mortality in sepsis. Shock 2009; 31:348-353.
36. Giamarellos-Bourboulis EJ, Kanellakopoulou K, Pelekanou A, et al. Kinetics of angiopoietin2 in serum of multi-trauma patients: Correlation with patient severity. Cytokine 2008; 44:310-313.
37. Ganter MT, Cohen MJ, Brohi K, et al. Angiopoietin2, marker and mediator of endothelial activation with prognostic significance early after trauma? Ann Surg 2008; 247: 320-326. (Pubitemid 351156777)
38. Kayal S, Jaïs JP, Aguini N, et al. Elevated circulating E-selectin, intracellular adhesion molecule 1, and von Willebrand factor in patients with severe infection. Am J Respir Crit Care Med 1998; 157:776-784.
39. Ware LB, Conner ER, Matthay MA: von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med 2001; 29:2325-2331. (Pubitemid 34038167)
40. Laudes IJ, Guo RF, Riedemann NC, et al. Disturbed homeostasis of lung intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 during sepsis. Am J Pathol 2004; 164:1435-1445. (Pubitemid 38387809)
41. Kumpers P, van Meurs M, David S, et al. Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis. Crit Care 2009; 13:1-9.
42. Kremer Hovinga JA, Zeerleder S, Kessler P, et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 2007; 5:2284-2290. (Pubitemid 47617882)
43. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377.
44. Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal antitumor necrosis factor antibody F(ab)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-2182. (Pubitemid 39491795)
45. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: A double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009; 180:640-648.
46. Novotny NM, Lahm T, Markel TA, et al. Angiopoietin1 in the treatment of ischemia and sepsis. Shock 2009; 31:335-341